GlobeStar Therapeutics Corp (GSTC)

[Bigfootbud]

GlobeStar Therapeutics Corporation (OTC PINK:GSTC) has a mission is to pioneer biotechnology in transformative therapies for the management of chronic neurodegenerative diseases. In an initial study of Project Amethyst™ in Italy of 150 volunteers, 90 between 25 and 65 years of age with MS disease and 60 healthy volunteers, the average Expanded Disability Status Scale (EDSS) score for subjects with MS dropped by at least 1.3 points for pre-treatment and an average of 4.02 points after treatment. After 45 days of treatment, all subjects reported an improvement in balance and motor control of all extremities, and most reported an improvement in bladder control. GSTC is the exclusive global licensee of the Project Amethyst™ patents and patent applications.

https://rivercountry.newschannelnebraska.com/story/49081924/transformative-therapies-for-neurodegenerative-diseases-mou-with-advanced-innovative-partners-to-develop-clinical-studies-for-multiple-sclerosis-globestar-therapeutics-stock-symbol-gstc

About Advanced Innovative Partners
Advanced Innovative Partners is a private clinical stage company focused on developing therapeutic and diagnostic radiopharmaceuticals for oncology, rare pediatric diseases, infectious disease and biomedical countermeasures The company's robust nuclear medicine product portfolio includes specialty pharmaceuticals enabling personalized medicine. For additional information about AIP please visit www.advancedinnovativepartners.com

https://finance.yahoo.com/news/globestar-therapeutics-enters-mou-advanced-131500612.html